Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Post-Transplant Acute Limbic Encephalitis: Clinical Features and Relationship to HHV6
Neurol 69:156-165, Seeley,W.W.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
West Nile Encephalitis
BMJ 326:865-869, Solomon,T.,et al, 2003
Lupus and Zoster
Lancet 362:616, Douglas,K.M.J., 2003
Risk Factors for Postherpetic Neuralgia
Arch Int Med 157:1217-1224, 11661997., Choo,P.W.,et al, 1997
Seizures in Medically Complex Patients
Epilepsia 38:S55-S59, Boggs,J.G., 1997
Childhood Leukemia:Central Nervous System Abnormalities During and After Treatment
AJNR 17:295-310, Chen,C-Y.,et al, 1996
Ataxia-Telangiectasia in a Child with Vaccine-Associated Paralytic Poliomyelitis
J Pediatr 121:405-407, Pohl,K.R.E.,et al, 1992
A Referendum on Clinical Trial Research in Multiple Sclerosis:Opinion of Jekyll Island Workshop
Neurol 39:977-981, Noseworthy,J.H.,et al, 1989
Immunological Treatment for Multiple Sclerosis
Editorial, Lancet 1:699-7011989., , 1989
Reversible Common Variable Immunodeficiency Syndrome Induced by Phenytoin
Arch Int Med 149:1421-1422, Travin,M.,et al, 1989
Double-Masked Trial of Azathioprine in Multiple Sclerosis
British and Dutch Multiple Sclerosis Azathioprine Trial Group, Lancet 2:179-1831988., , 1988
Hyperbaric-Oxygen Treatment of Multiple Sclerosis
NEJM 308:181-186, Fischer,B.H.,et al, 1983
Intensive Immunosuppression in Progressive Multiple Sclerosis
NEJM 308:173-180, Hauser,S.L.,et al, 1983
Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child
NEJM 297:241, Davis,L.E.,et al, 1977